Jim Cramer Sees Eli Lilly As More Than A 'One-Trick Pony' After FDA Advisors Back Its Alzheimer's Drug: 'It's Ultimately Headed To A Trillion Dollar Valuation'
Portfolio Pulse from Benzinga Neuro
Jim Cramer has expressed strong confidence in Eli Lilly (NYSE: LLY), citing its diverse drug portfolio and recent FDA advisory panel endorsement of its Alzheimer's drug, donanemab. Cramer believes this could propel the company's valuation to a trillion dollars. The FDA panel's recommendation is seen as a positive step towards full approval, boosting investor sentiment.
June 12, 2024 | 3:52 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Jim Cramer mentioned NVIDIA Corp (NVDA) as a company that, along with Eli Lilly, is not overvalued and could be a good investment if the market dips.
While NVIDIA was mentioned as a good investment, the primary focus of the article is on Eli Lilly. Therefore, the impact on NVIDIA's stock price is minimal in the short term.
CONFIDENCE 70
IMPORTANCE 30
RELEVANCE 20
NEUTRAL IMPACT
Jim Cramer also mentioned Novo Nordisk A/S (NVO) as a company that, along with Eli Lilly, is not overvalued and could be a good investment if the market dips.
Novo Nordisk was mentioned as a good investment, but the primary focus of the article is on Eli Lilly. Therefore, the impact on Novo Nordisk's stock price is minimal in the short term.
CONFIDENCE 70
IMPORTANCE 30
RELEVANCE 20
POSITIVE IMPACT
Jim Cramer is optimistic about Eli Lilly's future, citing the FDA advisory panel's endorsement of its Alzheimer's drug, donanemab. This endorsement is seen as a significant step towards full FDA approval, which could boost the company's valuation to a trillion dollars.
The FDA advisory panel's unanimous recommendation for Eli Lilly's Alzheimer's drug, donanemab, is a strong positive indicator for the company's future. This, combined with its success in other drug markets, supports Cramer's optimistic valuation.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100